Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vivolution pushes forward PRF (platelet-rich fibrin) system with E7m

This article was originally published in Clinica

Executive Summary

Danish automated surgical sealant system developer Vivolution is to ramp up European sales of its Vivostat platelet-rich fibrin (PRF) technology, having secured Euro7m ($9.1m) in its third round of financing. The proceeds will also be used to initiate US clinical studies of the system for FDA approval. The round was led by French VC fund Seventure and Danish private equity firm Vecata. The Vivostat system, which is available widely as a device for the on-site preparation of autologous tissue sealant, has been developed to prepare platelet-rich fibrin for treating chronic wounds.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT047548

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel